PDCD1 and neoplasm: As reported, high immune cell infiltration (ICI)-scoring OC patients with better clinical overall survival (OS), higher tumor mutation burden (TMB), higher immune checkpoint expression (PD1, PD-L1, PD-L2 and CTLA4) and higher sensitivity to two first-line chemotherapy drugs (paclitaxel and cisplatin) might benefit from immunotherapy, which means that the ICI score is an effective prognosis-related biomarker of OC and can provide valuable information on the potential response to immunotherapy [14].